Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

doi:10.1084/jem.177.1.89

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Warren, H. S.
	Articles by Cavaillon, J. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Warren, H. S.
	Articles by Cavaillon, J. M.


Social Bookmarking

	What's this?

ARTICLES

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

HS Warren, SF Amato, C Fitting, KM Black, PM Loiselle, MS Pasternack and JM Cavaillon
Department of Medicine, Massachusetts General Hospital, Charlestown 02129.

The use of monoclonal antibodies (mAbs) directed to lipid A for the therapy of gram-negative sepsis is controversial. In an attempt to understand their biologic basis of action, we used a fluid-phase radioimmunoassay to measure binding between bacterial lipopolysaccharide (LPS) and two IgM mAbs directed to lipid A that are being evaluated for the treatment of gram-negative bacterial sepsis. Both antibodies bound 3H-LPS prepared from multiple strains of gram- negative bacteria when large excesses of antibody were used, although binding was modest and only slightly greater than control preparations. We also studied the ability of each anti-lipid A antibody to neutralize some of the biological effects of LPS in vitro. Despite large molar excesses, neither antibody neutralized LPS as assessed by the limulus lysate test, by a mitogenic assay for murine splenocytes, or by the production of cytokines interleukin (IL)-1, IL-6, or tumor necrosis factor from human monocytes in culture medium or in whole blood. Our experiments do not support the hypothesis that either of these anti- lipid A mAbs function by neutralizing the toxic effects of LPS.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Wong, K.-F., Luk, J. M., Cheng, R. H., Klickstein, L. B., Fan, S.-T. (2007). Characterization of two novel LPS-binding sites in leukocyte integrin {beta}A domain. FASEB J. 21: 3231-3239 [Abstract] [Full Text]
Birkenmeier, G., Nicklisch, S., Pockelt, C., Mossie, A., Steger, V., Glaser, C., Hauschildt, S., Usbeck, E., Huse, K., Sack, U., Bauer, M., Schafer, A. (2006). Polymyxin B-Conjugated {alpha}2-Macroglobulin as an Adjunctive Therapy to Sepsis: Modes of Action and Impact on Lethality. J. Pharmacol. Exp. Ther. 318: 762-771 [Abstract] [Full Text]
Moretti, E. W., Newman, M. F., Muhlbaier, L. H., Whellan, D., Petersen, R. P., Rossignol, D., McCants, C. B. Jr, Phillips-Bute, B., Bennett-Guerrero, E. (2006). Effects of Decreased Preoperative Endotoxin Core Antibody Levels on Long-term Mortality After Coronary Artery Bypass Graft Surgery. Arch Surg 141: 637-641 [Abstract] [Full Text]
Munford, R. S. (2005). Invited review: Detoxifying endotoxin: time, place and person. Innate Immunity 11: 69-84 [Abstract]
Hotchkiss, R. S., Karl, I. E. (2003). The Pathophysiology and Treatment of Sepsis. NEJM 348: 138-150 [Full Text]
Opal, S. M. (2002). The clinical relevance of endotoxin in human sepsis: a critical analysis. Innate Immunity 8: 473-476 [Abstract]
Zhang, G.-H., Mann, D. M., Tsai, C.-M. (1999). Neutralization of Endotoxin In Vitro and In Vivo by a Human Lactoferrin-Derived Peptide. Infect. Immun. 67: 1353-1358 [Abstract] [Full Text]
Nnalue, N. A. (1998). alpha -GlcNAc-1right-arrow2-alpha -Glc, the Salmonella Homologue of a Conserved Lipopolysaccharide Motif in the Enterobacteriaceae, Elicits Broadly Cross-Reactive Antibodies. Infect. Immun. 66: 4389-4396 [Abstract] [Full Text]
Steingrub, J. S. (1998). Novel Insights Into the Pathogenesis and Therapy of Circulatory Shock. SEMIN CARDIOTHORAC VASC ANESTH 2: 31-45 [Abstract]
Camerota, A.J., Logdberg, L., Lake, P., Larkin, V.A., Fink, M.P. (1997). Delayed therapy with a polymyxin B-dextran conjugate (PMX-622) improves survival in rabbits with Gram-negative peritonitis. Innate Immunity 4: 285-292 [Abstract]
Greisman, S.E., Johnston, C.A. (1997). Review: Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis. Innate Immunity 4: 123-153 [Abstract]
Cavaillon, J-M., Marie, C., Caroff, M., Ledur, A., Godard, I., Poulain, D., Fitting, C., Haeffner-Cavaillon, N. (1996). CD14/LPS receptor exhibits lectin-like properties. Innate Immunity 3: 471-480 [Abstract]
Fletcher, M. A., Kloczewiak, M., Loiselle, P. M., Amato, S. F., Black, K. M., Warren, H. S. (1996). TALF peptide-immunoglobulin G conjugates that bind lipopolysaccharide. Innate Immunity 3: 49-55 [Abstract]
Lagrange, P.H., Blanchard, H.S., Felten, A. (1995). Review: Bacterial endotoxin and the human monoclonal antibody HA-IA: specificity, potential mechanisms of action, and limits to its effectiveness. Innate Immunity 2: 371-386 [Abstract]
Cross, A.S., Opal, S. (1994). Minireview: Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?. Innate Immunity 1: 57-69 [Abstract]